Cited by 443Systemic Lupus Erythematosus ResearchNeutrophil, Myeloperoxidase and Oxidative MechanismsVasculitis and related conditions

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice

Open access
Knight, Jason S, Subramanian, Venkataraman, O'Dell, Alexander A, Yalavarthi, Srilakshmi, Zhao, Wenpu, Smith, Carolyne K, Hodgin, Jeffrey B, Thompson, Paul R, Kaplan, Mariana J·2015·Annals of the Rheumatic Diseases

Abstract

Objectives An imbalance between neutrophil extracellular trap (NET) formation and degradation has been described in systemic lupus erythematosus (SLE), potentially contributing to autoantigen externalisation, type I interferon synthesis and endothelial damage. We have demonstrated that peptidylarginine deiminase (PAD) inhibition reduces NET formation and protects against lupus-related vascular damage in the New Zealand Mixed model of lupus. However, another strategy for inhibiting NETs--knockout of NOX2--accelerates lupus in a different murine model, MRL/lpr. Here, we test the effects of PAD inhibition on MRL/lpr mice in order to clarify whether some NET inhibitory pathways may be consistently therapeutic across models of SLE.Methods NET formation and autoantibodies to NETs were characterised in lupus-prone MRL/lpr mice. MRL/lpr mice were also treated with two different PAD inhibitors, Cl-amidine and the newly described BB-Cl-amidine. NET formation, endothelial function, interferon signature, nephritis and skin disease were examined in treated mice.Results Neutrophils from MRL/lpr mice demonstrate accelerated NET formation compared with controls. MRL/lpr mice also form autoantibodies to NETs and have evidence of endothelial dysfunction. PAD inhibition markedly improves endothelial function, while downregulating the expression of type I interferon-regulated genes. PAD inhibition also reduces proteinuria and immune complex deposition in the kidneys, while protecting against skin disease.Conclusions PAD inhibition reduces NET formation, while protecting against lupus-related damage to the vasculature, kidneys and skin in various lupus models. The strategy by which NETs are inhibited will have to be carefully considered if human studies are to be undertaken.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2014-205365

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

Sorted by citations

Metadata

Authors
Knight, J. S., Subramanian, V., O'Dell, A. A., Yalavarthi, S., Zhao, W., Smith, C. K., Hodgin, J. B., Thompson, P. R., & Kaplan, M. J.
Affiliations
  • University of Michigan (US)
  • Scripps Research Institute (US)
  • National Institutes of Health (US)
Corresponding author
Kaplan, Mariana J
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2015-12
Volume
74
Issue
12
Pages
2199-2206
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2159514587
Cited by
443
References
53
Citations by year
2026: 31 · 2025: 34 · 2024: 42 · 2023: 40 · 2022: 50 · 2021: 44 · 2020: 33 · 2019: 46 · 2018: 43 · 2017: 30 · 2016: 30 · 2015: 20
FWCI
22.16
Type
journal article
Language
en
Open access
Locations
  • Annals of the Rheumatic Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
Funders
  • National Institutes of Health (Z99 AR999999)
  • National Heart, Lung, and Blood Institute (HL088419, R01HL088419)
  • National Cancer Institute (R01CA151304, CA151304)
  • National Institute of General Medical Sciences (R01GM079357, GM 079357)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Life Sciences › Immunology and Microbiology › Immunology › Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
Keywords
neutrophil extracellular traps, systemic lupus erythematosus, MRL/lpr mice, endothelial dysfunction, type I interferon, nephritis, proteinuria, immune complex deposition, skin diseases, vascular injury, Cl-amidine
MeSH terms
Protein-Arginine Deiminases, Amidines, Animals, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Hydrolases, Kidney Diseases, Lupus Erythematosus, Systemic, Vascular Diseases, Mice, Inbred MRL lpr, Mice, Extracellular Traps

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review